Übersicht
The project concerns investments in research and development (R&D) activities and in the construction of an advanced manufacturing plant that will be located in existing promoter facilities in Belgium.
The project aims at improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses. The project focuses on neuroscience and immunology in particular neuro-degeneration, neuro-inflammation and rare diseases as well as autoimmune diseases, which are mostly still underserved and leave a high clinical unmet need.
The project includes the construction of a new plant to manufacture pharmaceutical products. This activity is listed in the Annex II of the Environmental Impact Assessment (EIA) Directive. Whether a EIA under the directive 2014/52/EU is required and other environmental details will be verified during the project appraisal.
The Promoter is a private company not operating in the Utilities sector and not having a status of a contracting entity. Thus it is not covered by EU Directives on procurement.